Medtronic closes 1st phase of Symplicity renal denervation feasibility trial

Wed, 10/03/2012 - 11:32am
Mass Device

Medtronic said the 1st phase of a small trial of the next iteration of its Symplicity device for treating high blood pressure showed a 100% success rate.


Medtronic (NYSE:MDT) said it's closed the 1st phase of a feasibility trial for its next-generation Symplicity renal denervation device for high blood pressure.

The 9-patient trial delivered a 100% acute success rate in accessing the renal arteries and delivering the therapy, according to a press release.

"We look forward to moving forward with our clinical evaluation of this next-generation system that aims to augment our portfolio by offering more sophisticated features that should benefit both physicians and patients," Medtronic's president of coronary & renal denervation Sean Salmon said in prepared remarks. "This feasibility study represents Medtronic's commitment to providing physicians with a broader range of solutions for performing renal denervation and to collaborating with physician partners in the ongoing evaluation of this ground-breaking therapy."


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.